 NeuroBo Pharmaceuticals, Inc. Nasdaq: NRBO, a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced that it has closed its previously announced registered direct offering of 750,000 shares of its common stock at a price of 10.00 per share, for aggregate gross proceeds of approximately 7.5 million. The Company intends to use the net proceeds from this offering for working capital, capital expenditures and general corporate purposes. 